Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration

Open access
Ding, Jin-Dong, Johnson, Lincoln V., Herrmann, Rolf, Farsiu, Sina, Smith, Stephanie G., Groelle, Marybeth, Mace, Brian E., Sullivan, Patrick, Jamison, Jeffrey A., Kelly, Una, Harrabi, Ons, Bollini, Sangeetha Subbarao, Dilley, Jeanette, Kobayashi, Dione, Kuang, Bing, Li, Wenlin, Pons, Jaume, Lin, John C., Rickman, Catherine Bowes·2011·Proceedings of the National Academy of Sciences

Abstract

Age-related macular degeneration (AMD) is a leading cause of visual dysfunction worldwide. Amyloid β (Aβ) peptides, Aβ1–40 (Aβ40) and Aβ1–42 (Aβ42), have been implicated previously in the AMD disease process. Consistent with a pathogenic role for Aβ, we show here that a mouse model of AMD that invokes multiple factors that are known to modify AMD risk (aged human apolipoprotein E 4 targeted replacement mice on a high-fat, cholesterol-enriched diet) presents with Aβ-containing deposits basal to the retinal pigmented epithelium (RPE), histopathologic changes in the RPE, and a deficit in scotopic electroretinographic response, which is reflective of impaired visual function. Strikingly, these electroretinographic deficits are abrogated in a dose-dependent manner by systemic administration of an antibody targeting the C termini of Aβ40 and Aβ42. Concomitant reduction in the levels of Aβ and activated complement components in sub-RPE deposits and structural preservation of the RPE are associated with anti-Aβ40/42 antibody immunotherapy and visual protection. These observations are consistent with the reduction in amyloid plaques and improvement of cognitive function in mouse models of Alzheimer's disease treated with anti-Aβ antibodies. They also implicate Aβ in the pathogenesis of AMD and identify Aβ as a viable therapeutic target for its treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1100901108

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 188

Metadata

Authors
Ding, J.-D., Johnson, L. V., Herrmann, R., Farsiu, S., Smith, S. G., Groelle, M., Mace, B. E., Sullivan, P., Jamison, J. A., Kelly, U., Harrabi, O., Bollini, S. S., Dilley, J., Kobayashi, D., Kuang, B., Li, W., Pons, J., Lin, J. C., & Rickman, C. B.
Venue
Proceedings of the National Academy of Sciences
Published
2011-06-20
Volume
108
Issue
28
Pages
E279-87
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2115932454
Cited by
188
References
31
FWCI
16.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. https://app.cochat.ai/papers/10.1073/pnas.1100901108
The paper
Ding, J.-D., Johnson, L. V., Herrmann, R., Farsiu, S., Smith, S. G., Groelle, M., Mace, B. E., Sullivan, P., Jamison, J. A., Kelly, U., Harrabi, O., Bollini, S. S., Dilley, J., Kobayashi, D., Kuang, B., Li, W., Pons, J., Lin, J. C., & Rickman, C. B. (2011). Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1100901108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.